Home / News / US’ Kimberly-Clark elects Joseph Romanelli to board of directors

US' Kimberly-Clark elects Joseph Romanelli to board of directors

18 Nov '24
1 min read
US' Kimberly-Clark elects Joseph Romanelli to board of directors
Joseph Romanelli. Pic: Merck

Insights

  • Kimberly-Clark has appointed Joseph Romanelli, president of Human Health International at Merck, to its board of directors, increasing the board size to 13.
  • Romanelli brings global leadership experience and expertise in science and healthcare.
  • He has led MSD's international markets since 2022 and previously served as CEO of JiXing Pharmaceuticals.
Kimberly-Clark Corporation has announced that Joseph Romanelli, president of Human Health International for Merck & Co, (MSD) has been elected to its board of directors, effective immediately. In connection with the election, Kimberly-Clark's board size will increase from 12 to 13 directors.

"Joe Romanelli is an outstanding addition to the Kimberly-Clark board of directors," said Mike Hsu, chairman and chief executive officer of Kimberly-Clark. "As we advance our powering care strategy, we will benefit from Romanelli’s global leadership experience and his expertise in using leading-edge science to save and improve lives around the world."

Romanelli has served as president of human health international for MSD, a global healthcare company that develops and manufactures medicines, vaccines, biologic therapies, and animal health products, since 2022. In this role, he oversees MSD's 75-plus markets outside of the US and leads a team of 14,000 colleagues. Prior to joining MSD, Romanelli served as the chief executive officer of JiXing Pharmaceuticals, a China-based biopharmaceutical company. Previously, he served in a variety of strategic and operational roles with increasing responsibility at MSD and Schering-Plough for 25 years.

Fibre2Fashion News Desk (RR)

Leave your Comments

US' The Honest Company's revenue rises 15% to $99 mn in Q3 2024
US' The Honest Company's revenue rises 15% to $99 mn in Q3 2024

Follow us